[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480185":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":90,"collaborators":21,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":21,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":21,"enrollmentInfo":101,"targetDuration":21,"studyType":104,"phases":105,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Anbogen Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ABT-101","EXPERIMENTAL","Part 1- dose-escalation: ABT-101 in patients with advanced cancer disease\n\nPart 2- dose expansion: ABT-101 in patients with NSCLC with confirmed HER2 mutations",[13],"Drug: ABT-101",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will receive ABT-101 by oral administration on a 28-day cycle",[9],[20],"DBPR112",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Anbogen","CONTACT","+886-2-2742-1839","clinicaltrial@anbogen.com",[29,45,57,69,78],{"facility":30,"status":31,"city":32,"state":21,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Taichung Veterans General Hospital","RECRUITING","Taichung","40705","Taiwan","TW",{"type":37,"coordinates":38},"Point",[39,40],120.6839,24.1469,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":21,"phoneExt":21,"email":21},"Tsung-Ying Yang, M.D",{"facility":46,"status":31,"city":47,"state":21,"zip":48,"country":34,"countryCode":35,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"National Cheng Kung University Hospital","Tainan","70403",{"type":37,"coordinates":50},[51,52],120.21333,22.99083,{"lat":52,"lon":51},[55],{"name":56,"role":25,"phone":21,"phoneExt":21,"email":21},"Wu-Chou Su, M.D",{"facility":58,"status":31,"city":59,"state":21,"zip":60,"country":34,"countryCode":35,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"National Taiwan University Hospital","Taipei","10002",{"type":37,"coordinates":62},[63,64],121.52639,25.05306,{"lat":64,"lon":63},[67],{"name":68,"role":25,"phone":21,"phoneExt":21,"email":21},"Chia-Chi Lin, M.D",{"facility":70,"status":31,"city":59,"state":21,"zip":71,"country":34,"countryCode":35,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Taipei Medical Univresity Hospital","11031",{"type":37,"coordinates":73},[63,64],{"lat":64,"lon":63},[76],{"name":77,"role":25,"phone":21,"phoneExt":21,"email":21},"Chao-Hua Chiu, M.D",{"facility":79,"status":31,"city":80,"state":21,"zip":81,"country":34,"countryCode":35,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Chang Gung Memorial Hospital, Linkou","Taoyuan","33305",{"type":37,"coordinates":83},[84,85],121.29696,24.99368,{"lat":85,"lon":84},[88],{"name":89,"role":25,"phone":21,"phoneExt":21,"email":21},"Wen-Cheng Chang, M.D",{"type":91,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100480185","phase-1-phase-1b2-study-to-evaluate-abt-101-in-solid-tumor-and-nsclc-patients-100480185",false,"NCT05532696","Phase 1b\u002F2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","A Phase Ib\u002FII, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ABT-101 in Patients With Advanced Solid Tumors and HER2 Exon 20 Insertions Mutated Non- Small Cell Lung Cancer","Inclusion Criteria:\n\n* Male or female aged ≥ 20 years or adult age as per local regulations, at time of informed consent\n* Histologically or cytologically confirmed advanced solid tumor (Part 1) or NSCLC with HER2 mutations as determined by the central result (Part 2)\n* For patients in Part 2 only: Patients has measurable disease per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Part 1), 0 to 2 (Part 2)\n* Appropriate candidate for experimental therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known active or untreated central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* For patients in Part 2 only: Previously treated with EGFR or HER2 TKIs.\n* Serious acute or chronic infections\n* Received a live-virus vaccination\n* Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose.\n* Not recovered from prior- treatment toxicities to Grade ≤1\n* Major surgery within 28 days prior to the study treatment\n* Concurrent malignancy within 2 years prior to first dose\n* History or presence of clinically relevant cardiovascular abnormalities. QTcF ≥ 470 ms\n* Significant gastrointestinal disorder(s) that could interfere with absorption of ABT101\n* Known to have a history of alcoholism or drug abuse","ALL","18 Years",{"count":102,"type":103},61,"ESTIMATED","INTERVENTIONAL",[106,107],"PHASE1","PHASE2","A Phase 1b\u002F2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)",[110,111,112],"Advanced Solid Tumor","Non Small Cell Lung Cancer","HER2 Mutations",[9,114,112],"NSCLC","2024-06-21",{"date":117,"type":118},"2024-06-24","ACTUAL",{"date":120,"type":118},"2022-09-27",{"date":122,"type":103},"2027-05",{"name":5,"class":6},5]